INOFEA - Empowering Enzymes
INOFEA AG is a Swiss biotech company founded in 2014 in Basel by a group of entrepreneurs and scientists as a spin-off from the School of Life Sciences, University of Applied Sciences and Arts, Northwestern Switzerland (FHNW), led by CEO Dr Yves Dudal.
At INOFEA, we empower enzymes. Together with our team of scientists led by Dr Patrick Shahgaldian, Professor at FHNW and CSO of INOFEA, and with the help of our investors, we have developed enzzen©, a patented platform technology capable to fit enzymes to in vivo and process conditions.
We’ve created INOFEA from the desire to meet a critical need related to enzyme lack of stability and robustness: the possibility to provide enzymes with resistance to in vivo and process conditions, so that they could be fully deployed in the health industry.
Unlike other existing technologies, our innovative nanotechnology platform is capable of shielding sensitive enzymes and has positively demonstrated substantial benefits to customers in a number of health industry applications.
INOFEA is constantly investing in R&D for its proprietary technology, as well as diversifying its line of business with value-added products and services, from formulating new commercially available enzymes, to improve our client’s processes by embedding enzzen© to non-proprietary applications, or the development of our own line of therapeutics.